

Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–2018¹

Melanie Stecher,² Antoine Chaillon,² Christoph Stephan, Elena Knops, Niko Kohmer, Clara Lehmann, Josef Eberle, Johannes Bogner, Christoph D. Spinner, Anna Maria Eis-Hübinger, Jan-Christian Wasmuth, Guido Schäfer, Georg Behrens, Sanjay R. Mehta, Jörg Janne Vehreschild, Martin Hoenigl

We analyzed 1,397 HIV-1 *pol* sequences of antiretroviral therapy-naïve patients in a total of 7 university hospitals in Bonn, Cologne, Frankfurt, Hamburg, Hannover, and Munich, Germany. Phylogenetic and network analysis elucidated numerous cases of shared drug resistance mutations among genetically linked patients; K103N was the most frequently shared mutation.

The use of antiretroviral therapy (ART) has shown markedly decreased sickness and death rates in persons living with HIV (PLWH) (1–3). Meanwhile, the emergence of antimicrobial drug resistance in HIV-1 is raising public health concerns (4,5). Nationwide estimates of the prevalence of drug resistance

mutations (DRMs) are not available in Germany (6); the reported prevalence of transmitted HIV-1 DRMs differ across regions and risk groups from 10.4%–17.2%, as described in 2 cohort studies from the German ClinSurv-HIV cohort and the Cologne-Bonn cohort (6,7).

Information about the dynamics and patterns of HIV transmission within defined areas and communities remains incomplete. Thus, we combined phylogenetic analysis with clinical and sociodemographic data, to determine the spread and dynamics of HIV-1 DRMs in 6 metropolitan regions in Germany, including the cities with the highest rates of new HIV-1 infections in 2017: Munich (17.3/100,000 population), Cologne (13.3/100,000 population), and Frankfurt (12.3/100,000 population), (8). We conducted this retrospective study in a cooperative effort of partner sites of the Translational Platform HIV (TP-HIV) (Cologne, Germany) and the University of California, San Diego (San Diego, CA, USA). The study was approved by the local ethics committees of the university hospitals of Bonn, Cologne, Munich, Hannover, Frankfurt, and Hamburg. All study participants gave written informed consent.

The Study

We analyzed HIV-1 partial *pol* sequences (HXB2 position 2550–3356), obtained as part of clinical routine care, and sociodemographic data of PLWH who received HIV care at the university hospitals of Bonn, Cologne, Frankfurt, Hamburg, and Hannover and at 2 hospitals in Munich during 2001–2018. Patients could participate in the study if they had recently received their diagnosis of HIV-1 and were ART naïve; this conservative approach excluded participants for

Author affiliations: University of Cologne Faculty of Medicine, Cologne, Germany (M. Stecher, C. Lehmann, J.J. Vehreschild); University Hospital of Cologne, Cologne (M. Stecher, E. Knops, C. Lehmann, J.J. Vehreschild); German Center for Infection Research (DZIF), partner site Cologne, Cologne (M. Stecher, C. Lehmann, J.J. Vehreschild); University of California San Diego, San Diego, CA, USA (A. Chaillon, S.R. Mehta, M. Hoenigl); University Hospital of Frankfurt, Frankfurt am Main, Germany (C. Stephan, J.J. Vehreschild); LMU München, Munich, Germany (J. Eberle); German Center for Infection Research (DZIF), partner site Munich, Munich (J. Eberle, J. Bogner, C.D. Spinner); Department of the Ludwig-Maximilians-University, Munich (J. Bogner); Technical University of Munich School of Medicine, Munich (C.D. Spinner); University of Bonn Medical Center, Bonn, Germany (A.M. Eis-Hübinger); University Hospital of Bonn, Bonn (J.-C. Wasmuth); University Hospital Hamburg Eppendorf, Hamburg, Germany (G. Schäfer); Hannover Medical School, Hannover, Germany (G. Behrens); German Center for Infection Research (DZIF), partner site Hannover, Hannover, Germany (G. Behrens); San Diego Veterans Administration Medical Center, San Diego (S.R. Mehta); Medical University of Graz, Graz, Austria (M. Hoenigl)

DOI: <https://doi.org/10.3201/eid2610.191506>

¹Preliminary results from this study were presented at the Conference for Retroviruses and Opportunistic Infections (CROI) 2019, March 4–7, 2019, Seattle, Washington, USA.

²These first authors contributed equally to this article.

whom the exact start date of ART or history of prior ART was not accurately documented.

Blood samples were collected before ART initiation. We sequenced partial HIV-1 *pol* region as previously described (7,9). We set the mixed mutation calling threshold at $\geq 10\%$, consistent with Sanger sequencing sensitivity (10). We identified major DRMs by using the Stanford University Genotypic Resistance Interpretation HIVdb version 8.9, (<https://hivdb.stanford.edu>). We inferred the genetic transmission network as previously described (7,9,11); we inferred putative linkage for genetic distances $\leq 1.5\%$ (12) (Appendix, <https://wwwnc.cdc.gov/eid/article/26/10/19-1506-App1.pdf>).

We performed statistical analyses by using Stata version 14 (StataCorp LP, <https://www.stata.com>). We applied Fisher exact or χ^2 test and univariable and multivariable logistic regression models, as appropriate, to determine characteristics that are associated with shared DRM and clustering. A shared DRM was defined as any DRM present in ≥ 2 genetically linked persons.

Overall, 1,397 HIV-1 infected participants were included. Most were male (82.9%; 1,158/1,397), originated from Germany (69.6%; 972/1,397), and infected with HIV-1 subtype B (72.8%; 1,017/1,397). The most commonly reported transmission risk was men who have sex with men (MSM) (56.7%; 792/1,397) (Table 1).

We identified an overall prevalence of any DRM at the time of diagnosis, excluding polymorphic mutations, of 17.8% (95% CI 15.7%–19.8%), 248/1,397 participants. The proportion varied significantly ($p < 0.001$) by region, ranging from 9.1% (95% CI 5%–13%; 21/231) in Munich, up to 31.4% (95% CI 24%–38%; 53/169) in Hannover. Resistance mutations associated with nucleoside reverse transcriptase inhibitors (NRTIs) (172/1,397; 12.3%) were most frequent, followed by nonnucleoside reverse transcriptase inhibitors (NNRTIs) (124/1,397; 8.9%). The most common single mutations related to NNRTIs were K103N (31/124; 25.0%), and G190A (8/124; 6.5%). Of the NRTI resistance mutations, M41L (25/172; 14.5%), and T215S (18/172; 10.5%) were most frequently observed (Table 2).

Table 1. Characteristics of study participants with HIV harboring drug resistance mutations, Germany, 2001–2018*

| Characteristic | No. (%) participants | No. (%) with DRMs | No. (%) with shared DRMs† | p value‡ |
|-------------------------|----------------------|-------------------|---------------------------|--------------|
| Total | 1,397 (100) | 248 (17.8) | 19 (8.1) | |
| Age, y | | | | 0.032 |
| >45 | 430 (30.8) | 82 (19.1) | 2 (0.5) | |
| 25–45 | 856 (61.3) | 145 (16.9) | 13 (1.5) | |
| <25 | 111 (7.9) | 21 (18.9) | 4 (3.6) | |
| Sex | | | | 0.059 |
| F | 239 (17.1) | 39 (16.3) | 0 | |
| M | 1,158 (82.9) | 209 (18.0) | 19 (1.6) | |
| HIV subtype | | | | 0.003 |
| Non-B | 380 (27.2) | 65 (17.1) | 0 | |
| B | 1,017 (72.8) | 183 (17.9) | 19 (1.9) | |
| Transmission risk§ | | | | 0.164 |
| HTS | 302 (21.6) | 48 (15.9) | 2 (0.7) | |
| MSM | 792 (56.7) | 138 (17.4) | 15 (1.9) | |
| Endemic | 133 (9.5) | 22 (16.5) | 0 | |
| PWID | 24 (1.7) | 4 (16.7) | 1 (4.2) | |
| Other/Unknown | 146 (10.5) | 36 (24.7) | 1 (0.7) | |
| Country of origin | | | | 0.104 |
| Germany | 972 (69.6) | 181 (18.6) | 17 (1.7) | |
| Other | 373 (26.7) | 58 (15.5) | 1 (0.3) | |
| Unknown | 52 (3.7) | 9 (17.3) | 1 (1.9) | |
| City | | | | 0.051 |
| Cologne | 582 (41.7) | 110 (18.9) | 14 (2.4) | |
| Hamburg | 48 (3.4) | 9 (18.8) | 0 | |
| Bonn | 152 (10.9) | 22 (14.5) | 3 (1.9) | |
| Frankfurt | 215 (15.4) | 33 (15.4) | 1 (0.5) | |
| Hannover | 169 (12.1) | 53 (31.4) | 1 (5.9) | |
| Munich | 231 (16.5) | 21 (9.1) | 0 | |
| Year of HIV-1 diagnosis | | | | 0.206 |
| 2001–2006 | 103 (7.4) | 14 (13.6) | 0 | |
| 2007–2012 | 705 (50.5) | 130 (18.4) | 13 (1.8) | |
| 2013–2018 | 589 (42.2) | 104 (17.7) | 6 (1.0) | |

*DRM, drug resistance mutation; endemic, recent immigration from a country with a HIV prevalence $> 1\%$; HTS, heterosexuals; MSM, men who have sex with men; PWID, persons who injected drugs.

†Shared DRM were defined as any DRM present in ≥ 2 genetically linked patients ($\leq 1.5\%$ GD)

‡Fisher exact and χ^2 test were performed as appropriate. Bold text indicates significant results.

§Polymorphic mutations are not included in the prevalence of DRMs.

Transmission network analyses revealed that 20.7% (289/1,397) of participants had a putative linkage forming 102 transmission clusters. The largest cluster included 12 participants, mostly MSM from Bonn, Cologne, Munich, and Frankfurt (Figure 1, panels A, B). Participants <25 years and 25–45 years of age were significantly more likely to cluster compared with participants >45 years (<25 years, adjusted OR [aOR] 4.38, 95% CI 2.55–7.52, $p < 0.001$; 25–45 years, aOR 1.91, 95% CI 1.36–2.678; $p < 0.001$). Participants infected with HIV-1 subtype B were more likely to cluster than those with non-B subtype (aOR 4.05, 95% CI 2.37–6.90; $p < 0.001$). Geospatial distribution differed; participants from Bonn were linked significantly more often than those from Cologne (aOR 1.63; 95% CI 1.06–2.49; $p = 0.025$), even though the cities are geographically close (Appendix Table).

The prevalence of transmitted DRM was comparable in clustering (47/289, 16.3%) and nonclustering (201/1,108; 18.1%) participants ($p = 0.46$) (Appendix Table). Of the 47 sequences harboring DRM, 19 (40.4%) were preferentially shared by participants living predominantly in Cologne (14/19, 73.7%) and Bonn (3/19, 15.8%) (Figure 2, panel A) and by participants reporting MSM as main risk factor (15/19; 78.9%) (Figure 2, panel B). Younger age (<25 years) was associated with a higher proportion of shared DRM (3/11; 3.5%) compared with older age (24–45 years, 13/856 [1.5%]; >45 years, 2/430 [0.5%]) (Table 1).

The most frequently observed putatively shared DRM was K103N, detected in 9/19 (47.4%) participants forming 4 distinct clusters, predominantly originating from Cologne (7/9, 77.8%). The second

Table 2. Proportion of identified drug resistance mutations in newly infected antiretroviral-naive patients with HIV-1, Germany, 2001–2018*

| Mutation | Bonn, no. (%) | Cologne, no. (%) | Frankfurt, no. (%) | Hamburg, no. (%) | Hannover, no. (%) | Munich, no. (%) |
|--------------|---------------|------------------|--------------------|------------------|-------------------|-----------------|
| NRTI | | | | | | |
| T215FY | 3 (1.21) | 19 (7.66) | 4 (1.61) | 1 (0.40) | 19 (7.66) | 6 (2.42) |
| M41L | 1 (0.40) | 13 (5.24) | 3 (1.21) | 1 (0.40) | 6 (2.42) | 1 (0.40) |
| D67GNS | 3 (1.21) | 13 (5.24) | 0 | 0 | 3 (1.21) | 1 (0.40) |
| K219ERQ | 3 (1.21) | 7 (2.82) | 1 (0.40) | 0 | 3 (1.21) | 2 (0.81) |
| M184IV | 0 | 9 (3.63) | 0 | 0 | 3 (1.21) | 1 (0.40) |
| A62V | 0 | 1 (0.40) | 1 (0.40) | 1 (0.40) | 3 (1.21) | 1 (0.40) |
| E44D | 0 | 4 (1.61) | 1 (0.40) | 0 | 2 (0.81) | 0 |
| K70RT | 0 | 4 (1.61) | 0 | 0 | 2 (0.81) | 0 |
| L210W | 1 (0.40) | 2 (0.81) | 0 | 0 | 3 (1.21) | 0 |
| T69D | 1 (0.40) | 4 (1.61) | 0 | 0 | 1 (0.40) | 0 |
| F77L | 0 | 0 | 0 | 0 | 4 (1.61) | 0 |
| L74V | 0 | 4 (1.61) | 0 | 0 | 0 | 0 |
| K65R | 0 | 2 (0.81) | 0 | 0 | 1 (0.40) | 0 |
| V75AIM | 0 | 3 (1.21) | 0 | 0 | 0 | 0 |
| NNRTI | | | | | | |
| E138A† | 7 (2.82) | 21 (8.47) | 11 (4.44) | 1 (0.40) | 6 (2.42) | 3 (1.21) |
| K103ENT | 7 (2.82) | 16 (5.13) | 5 (2.02) | 2 (0.81) | 4 (1.61) | 3 (1.21) |
| V179DEF | 0 | 11 (4.44) | 4 (1.61) | 2 (0.81) | 8 (3.23) | 5 (2.02) |
| G190AERS | 2 (0.81) | 9 (3.63) | 0 | 0 | 2 (0.81) | 1 (0.40) |
| Y188LHC | 2 (0.81) | 4 (1.61) | 0 | 0 | 2 (0.81) | 1 (0.40) |
| L100IV | 0 | 2 (0.81) | 3 (1.21) | 0 | 3 (1.21) | 0 |
| Y181C | 1 (0.40) | 3 (1.21) | 0 | 0 | 1 (0.40) | 1 (0.40) |
| V108I | 1 (0.40) | 3 (1.21) | 0 | 0 | 1 (0.40) | 0 |
| P225H | 1 (0.40) | 3 (1.21) | 0 | 0 | 0 | 0 |
| V106AIM | 0 | 4 (1.61) | 0 | 0 | 0 | 0 |
| M230MI | 0 | 2 (0.81) | 0 | 0 | 0 | 0 |
| A98AG | 0 | 1 (0.40) | 0 | 0 | 0 | 0 |
| F227FL | 0 | 1 (0.40) | 0 | 0 | 0 | 0 |
| H221HY | 0 | 1 (0.40) | 0 | 0 | 0 | 0 |
| K101E | 0 | 0 | 0 | 0 | 1 (0.40) | 0 |
| K238T | 0 | 1 (0.40) | 0 | 0 | 0 | 0 |
| PI | | | | | | |
| L90M | 0 | 0 | 0 | 0 | 5 (2.02) | 1 (0.40) |
| M46I | 0 | 0 | 1 (0.40) | 1 (0.40) | 2 (0.81) | 0 |
| I84V | 0 | 0 | 0 | 0 | 2 (0.81) | 0 |
| I47V | 0 | 0 | 0 | 1 (0.40) | 0 | 0 |
| L90LM | 0 | 0 | 0 | 0 | 1 (0.40) | 0 |
| M46L | 0 | 0 | 1 (0.40) | 0 | 0 | 0 |
| V82L | 0 | 0 | 0 | 0 | 0 | 1 (0.40) |

*Data are presented by each city's university hospital as absolute numbers and percentages. No resistances to integrase strand transfer inhibitors were identified. NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.

†E138A was not included in the drug resistance mutation/transmitted drug resistance mutation rate of our study population.




Figure 1. Transmission network analysis by sex and location (A) and by characteristic (B) for 1,397 patients with HIV, Germany, 2001–2018. Endemic, recent immigration from a country with HIV prevalence >1%; HTS, heterosexual patient; MSM, men who have sex with men; NA, not available; PWID, persons who inject drugs.

most common shared DRM was D67N, found in 6/19 (31.6%) participants from Cologne and Bonn.

Conclusions

The increasing prevalence of DRMs in PLWH has become a serious matter of concern for clinicians and public health entities (4). In our study, we observed a 17.8% prevalence of DRMs, higher than in previous studies (6,7). The proportion of NNRTI resistance mutations was 8.9%, which is potentially associated with the common use of NNRTI in first-line ART regimens. K103N represented one quarter of NNRTI resistance mutations, reducing susceptibility to the first-generation drugs nevirapine and efavirenz (13). Transmission network analyses revealed that K103N was the most frequently shared DRM.

K65R, K70RT, and M184IV were the most common of the NRTI resistance mutations we observed, particularly among the risk group of MSM living in Cologne and Hannover, indicating potential resistance to preexposure prophylaxis (PrEP) with tenofovir/emtricitabine. Such resistance might be an upcoming challenge as PrEP use increases. Monitoring for HIV infections with these mutations is of utmost importance for preventing an epidemic among high-risk PrEP users; one mitigation is to consider alternative PrEP regimens in regions with high resistance.

Our study had several limitations. First, our sample population could have been biased because participants were not randomly selected; our dataset was limited to ART-naïve patients who received an HIV diagnosis at 7 university hospitals during 2001–2018. Although




Figure 2. Presence of drug resistance mutations by location (A) and by risk factor (B) for 1,397 patients with HIV, Germany, 2001–2018. DRM, drug resistance mutation; HTS, heterosexual; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PWID, persons who inject drugs.

we know no reason why a university hospital setting would not be representative of the region, it is possible that populations treated outside these centers may have different transmission networks and risks; results are not generalizable to the entire regions or nationwide. Second, mixing of heterosexual patients and MSM in clusters may be due to missing single or multiple risk factors. Thus, their role could not be represented in the transmission networks. Third, we have not tested clinical correlates and drug resistance; the clinical relevance was inferred from the Stanford database.

In summary, we found that the overall rate of DRM was high in Germany. Network analysis elucidated cases of shared DRMs among genetically linked persons, mainly in MSM-dominated clusters. Our findings highlight regional differences and illustrate the need to test MSM, especially younger men, for HIV regularly and to evaluate local HIV programs and adapt screening and treatment strategies to local epidemics.

This work was supported by funds from the German Center for Infection Research (DZIF) (grant no. NCT02149004) and supported by the NIH grants (grant nos. AI036214, MH113477, and AI106039). M.H. received grant funding from Gilead.

The study was approved by the local ethics committees of the university hospitals of Bonn (reference no. 279-14), Cologne (reference no. 13-364), Munich (reference no. 438-14), Hannover (reference no. 279-14), Frankfurt (reference no. 279-14), and Hamburg (reference no. 279-14).

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

About the Author

Dr. Stecher is an epidemiologist in the Department for Infectious Diseases at the University Hospital of Cologne, Germany. Her primary research interests are infectious diseases, HIV epidemiology, and cohort studies.

References

1. Glass TR, Sterne JA, Schneider MP, De Geest S, Nicca D, Furrer H, et al.; Swiss HIV Cohort Study. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. *AIDS*. 2015;29:2195–200. <https://doi.org/10.1097/QAD.0000000000000782>
2. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiretroviral society-USA panel. *JAMA*. 2018;320:379–96. <https://doi.org/10.1001/jama.2018.8431>
3. Robert Koch-Institut. Epidemiologisches bulletin 47 [in German]. 2018 [cited 2020 Jul 31]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/47_18.pdf
4. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al.; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis*. 2011;11:363–71. [https://doi.org/10.1016/S1473-3099\(11\)70032-9](https://doi.org/10.1016/S1473-3099(11)70032-9)
5. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med*. 2002;347:385–94. <https://doi.org/10.1056/NEJMoa013552>
6. Schmidt D, Kollan C, Fätkenheuer G, Schülter E, Stellbrink HJ, Noah C, et al.; ClinSurv-HIV Drug Resistance Study Group in CHAIN. Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. *PLoS One*. 2014;9:e104474. <https://doi.org/10.1371/journal.pone.0104474>
7. Stecher M, Chaillon A, Eis-Hubinger AM, Lehmann C, Fätkenheuer G, Wasmuth JC, et al. Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. *Clin Microbiol Infect*. 2019 Feb;25:253.e1–253.e4. <https://doi.org/10.1016/j.cmi.2018.09.025>
8. Robert Koch-Institut. Epidemiologisches Bulletin 39 [in German]. 2017 [cited 2020 Jul 31]. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/39_17.pdf
9. Stecher M, Chaillon A, Eberle J, Behrens GMN, Eis-Hübinger AM, Lehmann C, et al. Molecular epidemiology of the HIV epidemic in three German metropolitan regions – Cologne/Bonn, Munich, and Hannover, 1999–2016. *Sci Rep*. 2018;8:6799. <https://doi.org/10.1038/s41598-018-25004-8>
10. Döring M, Büch J, Friedrich G, Pironti A, Kalaghatgi P, Knops E, et al. geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data. *Nucleic Acids Res*. 2018;46(W1):W271–7. <https://doi.org/10.1093/nar/gky349>
11. Kosakovsky Pond SL, Weaver S, Leigh Brown AJ, Wertheim JO. HIV-TRACE (TRAnsmiSSion Cluster Engine): a tool for large scale molecular epidemiology of HIV-1 and other rapidly evolving pathogens. *Mol Biol Evol*. 2018;35:1812–9. <https://doi.org/10.1093/molbev/msy016>
12. Wertheim JO, Leigh Brown AJ, Hepler NL, Mehta SR, Richman DD, Smith DM, et al. The global transmission network of HIV-1. *J Infect Dis*. 2014;209:304–13. <https://doi.org/10.1093/infdis/jit524>
13. European AIDS Clinical Society (EACS). European guidelines for treatment of HIV-positive adults in Europe 9.1. 2018 [cited 2020 Jul 31]. http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf

Address for correspondence: Martin Hoenigl, Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, 200 West Arbor Dr #8208, San Diego, CA 92103, USA; email: mhoenigl@ucsd.edu; Melanie Stecher, Department I for Internal Medicine, University Hospital of Cologne, Herderstraße 52-54, 50931 Köln, Germany; email: melanie.stecher@uk.koeln.de

Pretreatment HIV Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–2018

Appendix

Sequence and Transmission Network Analysis

Analysis was performed using one HIV-1 partial *pol* sequence from each unique individual (HXB2 position 2550–3356) obtained at the first HIV clinic visit. The Subtype Classification using Evolutionary Algorithms (SCUEAL) program was used to subtype all sequences and the HIV-TRACE software (HIV TRANsmiSSion Cluster Engine; www.hivtrace.org) was used to infer putative transmission clusters (1,2). All partial HIV-1 *pol* sequences were aligned to the HXB2 reference sequence. Putative transmission links (i.e., edges) were inferred when 2 sequences (i.e. nodes) had a Tamura-Nei 93 genetic distance of $\leq 1.5\%$ (3). The $\leq 1.5\%$ threshold has been established as a standard in the field, and is based on study findings showing that within mono-infected persons, *pol* sequences typically do not diverge $>1\%$ during the first 10 years of infection. All nucleotide ambiguities were resolved and only sequences with $<1.5\%$ diversity were retained. Multiple linkages were then combined into putative clusters. Clusters comprised of only 2 linked individuals were identified as dyads. We assessed potential confounding effects of convergent evolution for drug resistances by repeating our analysis after we have excluded 48 codon positions in protease and reverse transcriptase, which are associated with drug resistance (4,5).

Appendix Table. Demographics and characteristics of patients with HIV and results of univariate and multivariate transmission analysis, Germany, 2001–2018*

| Characteristic | Nonclustering no. (%) | Clustering no. (%) | Univariate analysis | | Multivariable analysis | |
|-------------------------|--------------------------|-----------------------|---------------------|------------------|------------------------|------------------|
| | | | OR 95% CI | p-value | OR 95% CI | p-value† |
| Total | 1,108 (79.3) | 289 (20.7) | | | | |
| Age, y | | | | | | |
| >45 | 367 (85.3) | 63 (14.7) | Ref | | Ref | |
| 25–45 | 671 (78.4) | 185 (21.6) | 1.60 (1.18–2.20) | 0.003 | 1.91 (1.36–2.68) | <0.001 |
| <25 | 70 (63.1) | 41 (36.9) | 3.41 (2.14–5.45) | <0.001 | 4.38 (2.55–7.52) | <0.001 |
| DRM | | | | | | |
| No | 907 (78.2) | 242 (21.1) | Ref | | | |
| Yes | 201 (84.8) | 47 (19.0) | 0.88 (0.62–1.24) | 0.457 | | |
| Sex | | | | | | |
| F | 222 (92.90) | 17 (7.1) | Ref | | Ref | |
| M | 886 (76.5) | 272 (23.5) | 4.01 (2.40–6.69) | <0.001 | 1.62 (0.85–3.06) | 0.140 |
| HIV subtype | | | | | | |
| non-B | 360 (94.7) | 20 (5.3) | Ref | | Ref | |
| B | 748 (73.5) | 269 (26.5) | 6.47 (4.04–10.37) | <0.001 | 4.05 (2.37–6.90) | <0.001 |
| Transmission risk | | | | | | |
| HTS | 253 (83.8)) | 49 (16.2) | Ref | | Ref | |
| MSM | 580 (73.2) | 212 (26.8) | 1.89 (1.34–2.66) | <0.001 | 0.89 (0.58–1.38) | 0.623 |
| Endemic | 133 (100) | - | NA | | NA | |
| PWID | 21 (87.5) | 3 (12.5) | 0.74 (0.21–2.57) | 0.633 | 0.59 (0.15–2.29) | 0.586 |
| Others/Unknown | 121 (82.9) | 25 (17.1) | 1.07 (0.63–1.81) | 0.810 | 0.92 (0.50–1.69) | 0.922 |
| Country of origin | | | | | | |
| Germany | 733 (75.4) | 239 (24.6) | Ref | | Ref | |
| Other | 333 (89.3) | 40 (10.7) | 0.37 (0.26–0.53) | <0.001 | 0.70 (0.47–1.06) | 0.095 |
| Unknown | 42 (80.8) | 10 (19.2) | 0.73 (0.36–1.48) | 0.382 | 0.88 (0.40–1.90) | 0.736 |
| City | | | | | | |
| Cologne | 444 (76.3) | 138 (47.8) | Ref | | Ref | |
| Hamburg | 47 (97.9) | 1 (2.1) | 0.07 (0.01–0.50) | 0.008 | NA | |
| Bonn | 94 (61.8) | 58 (38.2) | 1.99 (0.62–1.31) | <0.001 | 1.63 (1.06–2.49) | 0.025 |
| Frankfurt | 168 (78.1) | 47 (21.9) | 0.90 (0.62–1.31) | 0.583 | 0.81 (0.52–1.25) | 0.342 |
| Hannover | 163 (96.4) | 6 (3.6) | 0.12 (0.05–2.73) | <0.001 | 0.10 (0.01–0.36) | <0.001 |
| Munich | 192 (83.1) | 39 (16.9) | 0.65 (0.44–0.97) | 0.034 | 0.62 (0.40–0.94) | 0.025 |
| Year of HIV-1 diagnosis | | | | | | |
| 2001–2006 | 91 (88.3) | 12 (11.7) | Ref | | Ref | |
| 2007–2012 | 566 (80.3) | 139 (19.7) | 1.86 (0.99–3.49) | 0.053 | 2.59 (1.34–5.00) | 0.005 |
| 2013–2018 | 451 (76.6) | 138 (23.4) | 2.32 (1.23–4.36) | 0.009 | 3.36 (1.71–6.61) | <0.001 |

*The univariable and multivariable logistic regression model determined associating factors on clustering persons (clustering yes/no as dependent variable). Endemic, recent immigration from a country with HIV prevalence >1%; HTS, heterosexuals; MSM, men who have sex with men; NA, not applicable; PWID, persons who inject drugs; Ref, reference category for univariable and multivariable regression model.

†Univariate and multivariable logistic regression model. Bold text indicates significant results. We used the enter method to reach the best model that explained the data. Our final multivariable model was adjusted for age, sex, HIV subtype, reported risk group, country of origin, city of residence, and year of HIV-1 diagnosis.

References

1. Kosakovsky Pond SL, Weaver S, Leigh Brown AJ, Wertheim JO. HIV-TRACE (TRANsmiSSion Cluster Engine): a tool for large scale molecular epidemiology of HIV-1 and other rapidly evolving pathogens. *Mol Biol Evol.* 2018;35:1812–9. PubMed
<https://doi.org/10.1093/molbev/msy016>
2. Kosakovsky Pond SL, Posada D, Stawiski E, Chappey C, Poon AF, Hughes G, et al. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. *PLOS Comput Biol.* 2009;5:e1000581. PubMed
<https://doi.org/10.1371/journal.pcbi.1000581>

3. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol Biol Evol.* 1993;10:512–26. PubMed
4. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al.; Variant, Atypical, and Resistant HIV Surveillance Group. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.—2006. *AIDS.* 2010;24:1203–12. PubMed <https://doi.org/10.1097/QAD.0b013e3283388742>
5. Wertheim JO, Kosakovsky Pond SL. Purifying selection can obscure the ancient age of viral lineages. *Mol Biol Evol.* 2011; 28:3355–3365. <https://doi.org/10.1093/molbev/msr170>